Dual Drug Repurposing: The Example of Saracatinib
Open accessAbstract
Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer’s disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer’s disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Saracatinib (AZD0530) is a tyrosine kinase inhibitor undergoing Phase II trials and has been demonstrated to improve memory in transgenic mice models of AD.
“The tyrosine kinase inhibitor saracatinib (AZD0530 (labeled as 14, Figure 5)) is undergoing Phase II trials [174,175,176] and has been demonstrated to improve memory in transgenic mice models of AD.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409 · see citing works
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T. R., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,333 · see citing works
Role of Quinones in Toxicology
Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., & Monks, T. J. (2000) · Chemical Research in Toxicology · doi:10.1021/tx9902082 · Cited by 1,703 · see citing works
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · see citing works
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O. D., Young, M. A., Scheffzek, K., Veach, D. R., Bornmann, W. G., Clarkson, B., Superti‐Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 880 · see citing works
Bertoli, G. R., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 818 · see citing works
BMP type I receptor inhibition reduces heterotopic ossification
Yu, P. B., Deng, D. Y., Lai, C. S. C., Hong, C. C., Cuny, G. D., Bouxsein, M., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1888 · Cited by 635 · see citing works
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 611 · see citing works
Martin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599 · see citing works
Hennequin, L. F., Allen, J. M., Breed, J., Curwen, J., Fennell, M., Green, T. P., der Brempt, C. L., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 365 · see citing works
A review of network-based approaches to drug repositioning
Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J., & Green, J. R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbx017 · Cited by 330 · see citing works
Necroptosis in the Pathophysiology of Disease
Khoury, M. K., Gupta, K., Franco, S. R., & Liu, B. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.012 · Cited by 326 · see citing works
<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · see citing works
Hiscox, S., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W., & Nicholson, R. I. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274 · see citing works
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270 · see citing works
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238 · see citing works
Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex
Liu, X. J., Gingrich, J. R., Vargas‐Caballero, M., Dong, Y., Sengar, A. S., Beggs, S., Wang, S., Ding, H. K., Frankland, P. W., & Salter, M. W. (2008) · Nature Medicine · doi:10.1038/nm.1883 · Cited by 222 · see citing works
SRC: A Century of Science Brought to the Clinic
Aleshin, A. A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 212 · see citing works
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt238 · Cited by 201 · see citing works
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
Chang, Y.-M., Bai, L., Liu, S., Yang, J. C., Kung, H.-J., & Evans, C. P. (2008) · Oncogene · doi:10.1038/onc.2008.250 · Cited by 185 · see citing works
Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor
Mohedas, A. H., Xing, X., Armstrong, K. A., Bullock, A. N., Cuny, G. D., & Yu, P. B. (2013) · ACS Chemical Biology · doi:10.1021/cb300655w · Cited by 164 · see citing works
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0119-0 · Cited by 164 · see citing works
Panicker, N., Saminathan, H., Jin, H., Neal, M., Harischandra, D. S., Gordon, R., Kanthasamy, K. A., Lawana, V., Sarkar, S., Luo, J. D., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0302-15.2015 · Cited by 163 · see citing works
Targeting Fyn Kinase in Alzheimer’s Disease
Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works
Gucalp, A., Sparano, J. A., Caravelli, J. F., Santamauro, J. T., Patil, S. N., Abbruzzi, A., Pellegrino, C. M., Bromberg, J., Dang, C. T., Theodoulou, M., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.021 · Cited by 159 · see citing works
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158 · see citing works
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 144 · see citing works
Jäger, B., Schupp, J. C., Plappert, L., Terwolbeck, O., Artysh, N., Kayser, G., Engelhard, P., Adams, T. S., Zweigerdt, R., Kempf, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33193-0 · Cited by 142 · see citing works
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Justet, A., Adams, T. S., Readhead, B. P., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202010-3832oc · Cited by 116 · see citing works
Koppikar, P., Choi, S.-H., Egloff, A. M., Cai, Q., Suzuki, S., Freilino, M. L., Nozawa, H., Thomas, S. M., Gooding, W. E., Siegfried, J. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5226 · Cited by 113 · see citing works
Baselga, J. M., Cervantes, A. M. R., Martinelli, E., Chirivella, I., Hoekman, K., Hurwitz, H. I., Jodrell, D. I., Hamberg, P., Casado, E., Elvin, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0748 · Cited by 109 · see citing works
Therapeutic Targeting of Src Kinase in Myofibroblast Differentiation and Pulmonary Fibrosis
Hu, M., Che, P., Han, X., Cai, G., Liu, G., Antony, V. B., Luckhardt, T., Siegal, G. P., Zhou, Y., Liu, R.-M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216044 · Cited by 106 · see citing works
Lara, P. N., Longmate, J., Evans, C. P., Quinn, D. I., Twardowski, P. W., Chatta, G. S., Posadas, E. M., Stadler, W. M., & Gandara, D. R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328325a867 · Cited by 95 · see citing works
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92 · see citing works
Novel dual Src/Abl inhibitors for hematologic and solid malignancies
Schenone, S., Brullo, C., Musumeci, F., & Botta, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499898 · Cited by 83 · see citing works
McNeish, I. A., Ledermann, J. A., Webber, L., James, L. E., Kaye, S. B., Hall, M., Hall, G. D., Clamp, A. R., Earl, H. M., Banerjee, S. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu363 · Cited by 82 · see citing works
Toyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79 · see citing works
Fury, M. G., Baxi, S. S., Shen, R., Kelly, K. W., Lipson, B. L., Carlson, D. L., Stambuk, H. E., Haque, S. S., & Pfister, D. G. (2011) · PubMed · Cited by 75 · see citing works
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
Hiscox, S., Jordan, N., Smith, C. G., James, M., Morgan, L. D., Taylor, K. M., Green, T. P., & Nicholson, R. I. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0058-6 · Cited by 74 · see citing works
Tang, S. J., Fesharaki‐Zadeh, A., Takahashi, H., Nies, S. H., Smith, L. M., Luo, A., Chyung, A. S., Chiasseu, M., & Strittmatter, S. M. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00976-9 · Cited by 72 · see citing works
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Williams, E., Bagarova, J., Kerr, G., Xia, D.-D., Place, E., Dey, D., Shen, Y., Bocobo, G. A., Mohedas, A. H., Huang, X., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.95042 · Cited by 71 · see citing works
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67 · see citing works
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
Du, G., Wang, J., Zhang, T., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2229-2 · Cited by 65 · see citing works
Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64 · see citing works
Portugal, C. C., Almeida, T. O., Socodato, R., & Relvas, J. B. (2021) · FEBS Journal · doi:10.1111/febs.16197 · Cited by 61 · see citing works
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
Gangadhar, T. C., Clark, J. I., Karrison, T. G., & Gajewski, T. F. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9897-4 · Cited by 57 · see citing works
Lang, L., Shay, C., Zhao, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0827-1 · Cited by 57 · see citing works
Reddy, S. M., Kopetz, S., Morris, J. S., Parikh, N. U., Qiao, W., Overman, M. J., Fogelman, D. R., Shureiqi, I., Jacob, C., Malik, Z., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0257-z · Cited by 55 · see citing works
Lang, L., Shay, C., Xiong, Y., Thakkar, P., Chemmalakuzhy, R., Wang, X., & Teng, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0623-3 · Cited by 55 · see citing works
MacKay, H. J., Au, H., McWhirter, E., Alcindor, T., Jarvi, A., MacAlpine, K., Wang, L. E., Wright, J. J., & Oza, A. M. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9650-4 · Cited by 53 · see citing works
An Update On Dual Src/Abl Inhibitors
Musumeci, F., Schenone, S., Brullo, C., & Botta, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.29 · Cited by 53 · see citing works
Renouf, D. J., Moore, M. J., Hedley, D. W., Gill, S., Jonker, D. J., Chen, E. X., Walde, D., Goel, R., Southwood, B., Gauthier, I. C., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9611-3 · Cited by 53 · see citing works
Gubens, M. A., Burns, M. J., Perkins, S. M., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.008 · Cited by 51 · see citing works
The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells
Purnell, P. R., Mack, P. C., Tepper, C. G., Evans, C. P., Green, T. P., Gumerlock, P. H., Lara, P. N., Gandara, D. R., Kung, H.-J., & Gautschi, O. P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819c78fb · Cited by 50 · see citing works
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith, L. M., Zhu, R., & Strittmatter, S. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.042 · Cited by 47 · see citing works
Jin, J., Sun, Z., Yang, F., et al. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.03.015 · Cited by 45 · see citing works
Molina, J. R., Foster, N. R., Reungwetwattana, T., Nelson, G. D., Grainger, A. V., Steen, P. D., Stella, P. J., Marks, R. S., Wright, J., & Adjei, A. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.004 · Cited by 43 · see citing works
Formisano, L., D'Amato, V., Servetto, A., Brillante, S., Raimondo, L., Mauro, C. D., Marciano, R., Orsini, R. C., Cosconati, S., Randazzo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4636 · Cited by 42 · see citing works
Sharma, S., Carlson, S., Gregory‐Flores, A., Hinojo-Perez, A., Olson, A. E., & Thippeswamy, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105410 · Cited by 42 · see citing works
Laurie, S. A., Goss, G. D., Shepherd, F. A., Reaume, M. N., Nicholas, G. A., Philip, L., Wang, L. E., Schwock, J., Hirsh, V., Oza, A. M., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.08.001 · Cited by 35 · see citing works
Kaye, S. B., Aamdal, S., Jones, R. D., Freyer, G., Pujade-Lauraine, É., de Vries, E. G. E., Barriuso, J., Sandhu, S. K., Tan, D. S. W., Hartog, V., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.158 · Cited by 33 · see citing works
Powles, T. B., Brown, J. E., Larkin, J., Jones, R. J., Ralph, C., Hawkins, R. E., Chowdhury, S., Boleti, E., Bhal, A., Fife, K. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw014 · Cited by 32 · see citing works
Hannon, R. A., Finkelman, R. D., Clack, G., Iacona, R. B., Rimmer, M., Gossiel, F., Baselga, J. M., & Eastell, R. (2012) · Bone · doi:10.1016/j.bone.2011.12.017 · Cited by 31 · see citing works
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
McGivern, N., Helali, A. E., Mullan, P. B., McNeish, I. A., Harkin, D. P., Kennedy, R. D., & McCabe, N. (2017) · Oncotarget · doi:10.18632/oncotarget.23524 · Cited by 30 · see citing works
Fujisaka, Y., Onozawa, Y., Kurata, T., Yasui, H., Goto, I., Yamazaki, K., Machida, N., Watanabe, J., Shimada, H., Shi, X., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9809-7 · Cited by 28 · see citing works
Danson, S. J., Mulvey, M. R., Turner, L., Horsman, J. M., Escott, K. J., Coleman, R. E., Ahmedzai, S. H., Bennett, M., & Andrew, D. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100261 · Cited by 28 · see citing works
Baird, K., Glod, J. W., Steinberg, S. M., Reinke, D. K., Pressey, J. G., Mascarenhas, L., Federman, N. C., Marina, N. M., Chawla, S. P., Lagmay, J., et al. (2020) · Sarcoma · doi:10.1155/2020/7935475 · Cited by 28 · see citing works
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors
Jha, V., Macchia, M., Tuccinardi, T., & Poli, G. (2020) · Cancers · doi:10.3390/cancers12082327 · Cited by 26 · see citing works
Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL
Li, J., Liu, X., Liu, Y., Huang, F., Liang, J., Lin, Y., Hu, F., Feng, J., Han, Z., Chen, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06514-y · Cited by 26 · see citing works
Kettle, J. G., & Wilson, D. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.007 · Cited by 22 · see citing works
Trarbach, T., Schultheis, B. S., Gauler, T. C., Schneider, V., Strumberg, D., Eberhardt, W., Scouiller, S. L., Marotti, M., Brown, K. H., & Drevs, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9754-x · Cited by 21 · see citing works
Cytochrome P450 Mediated Bioactivation of Saracatinib
Chen, J., Peng, Y., & Zheng, J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00242 · Cited by 21 · see citing works
Roelants, C., Giacosa, S., Pillet, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25700 · Cited by 19 · see citing works
The Role of Src Family Kinases in Mast Cell Effector Function
Furumoto, Y., Gomez, G., González‐Espinosa, C., et al. (2005) · Novartis Foundation symposium · doi:10.1002/9780470033449.ch4 · Cited by 18 · see citing works
Assessment of the Metabolism and Intrinsic Reactivity of a Novel Catechol Metabolite
Hutzler, J. M., Melton, R. J., Rumsey, J. M., et al. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700429v · Cited by 17 · see citing works
Oswald, A. J., Symeonides, S. N., Wheatley, D. A., Chan, S. Y. T., Brunt, A. M., McAdam, K., Schmid, P., Waters, S. H., Poole, C. J., Twelves, C. J., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06873-8 · Cited by 15 · see citing works
Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells
Nowak, D., Boehrer, S., Hochmuth, S., Trepohl, B., Hofmann, W., Hoelzer, D. F., Hofmann, W., Mitrou, P. S., Ruthardt, M., & Chow, K. U. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3281721ff6 · Cited by 14 · see citing works
Smilde, B. J., Stockklausner, C., Keen, R. W., Whittaker, A., Bullock, A. N., von Delft, A., van Schoor, N. M., Yu, P. B., & Eekhoff, E. M. W. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05471-x · Cited by 14 · see citing works
Anti-allergic effect of the Src family kinase inhibitor saracatinib
Yamaki, K., Terashi, M., Ogura, S., et al. (2020) · Die Pharmazie · doi:10.31083/ph.2020.9949 · Cited by 6 · see citing works
Liu, Q., Wang, L., Li, D., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10596 · Cited by 5 · see citing works
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
White, R. E., Bannister, M. H., Day, A., Bergom, H. E., Tan, V. M., Hwang, J. H., Nguyen, H. D., & Drake, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210487 · Cited by 5 · see citing works
Pegram, M. D., Silva, O., Higgins, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13074 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
- Authors
- Ramos, R., & Vale, N.
- Affiliations
- Universidade do Porto (PT)
- Corresponding author
- Vale, Nuno
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-04-22
- Volume
- 25
- Issue
- 8
- Pages
- 4565
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11050334
- OpenAlex
- W4395011119
- Cited by
- 24
- References
- 82
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 3
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Fundo Europeu de Desenvolvimento Regional (FEDER) (IF/00092/2014/CP1255/CT0004)
- Fundação para a Ciência e a Tecnologia (FCT) (IF/00092/2014/CP1255/CT0004)
- Faculty of Medicine, University of Porto (FMUP) (IF/00092/2014/CP1255/CT0004)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Keywords
- saracatinib, AZD0530, drug repurposing, Alzheimer's disease, Fyn, pulmonary fibrosis, liver fibrosis, analgesia, anti-allergic activity, nanoparticle drug delivery, adverse effects, cancer therapy
- MeSH terms
- Alzheimer Disease, Animals, Antineoplastic Agents, Humans, Neoplasms, Quinazolines, src-Family Kinases, Protein Kinase Inhibitors, Benzodioxoles, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
